Relapses in patients with multiple relapses are very common. In our study, 44% of patients experienced relapse after a 12-month observation period, whereas 16.5% remained in a better status and 45.7% relapsed in an worse condition. The study provides a clear message for those who work hard to avoid relapse.
In a recent study, findings found that relapse can be prevented by integrating treatments into the recovery process. This would include the provision of psycho-education, relapse-intervention and maintenance training for families, doctors and nurses. Relapse prevention is important to patients' recovery and the development of stable recovery.
Relapse occurs following treatment, with a greater percentage of relapses occurring at the completion of treatment after having achieved remission. Further research in unraveling the molecular and genetic profiles related to this outcome will enhance our understanding.
People with first episode psychosis, and those currently in remission, will experience some degree of recurrent psychosis over a one year period. Overall, people experienced higher rates of relapse with the duration of time since first episode psychosis.
Relapse is the single largest cause of death from prostate cancer. We conclude that even with very low rates of relapse, a cure is highly unlikely. However, with ongoing treatment and evolving treatment approaches, a cure for relapse will become more feasible.
Symptoms of relapse vary according to the nature of the disorder; and for each symptom there is different information and assessment required. Therefore, the identification of a relapse in an individual is based on the symptoms as reported by the patient. This information can then be used to help manage relapse, for example to develop strategies to manage emotional symptoms and to deal with behavioural problems.
Findings from a recent study are consistent with previous studies in which the magnitude of change in symptom severity after a relapse is greater than that experienced with disease remission/control or with spontaneous remission.
The effectiveness of ar (compared with placebo) was supported by changes in attention. Findings add to the growing evidence for attentional retraining's efficacy in treating ADHD and the need to address attention in treatment of OCD.
It is difficult to attribute specific effects of attentional retraining to other factors. Future studies should use more objective measures of attentional processes and measures of outcomes of treatment, preferably over a longer time-frame. This article is protected by copyright. All rights reserved.
There is a wide inter-center variability in clinical trial response rates in relapsed Ewing sarcoma. Inclusion in clinical trials is strongly associated with a good clinical response to treatment. Clinical trials are a viable treatment option, at least for Ewing sarcoma patients.
Relapse to symptoms may occur in family members of patients with the same clinical disease and sub-clinical disease. This suggests that factors in the familial environment, or the disease phenotype, are involved in relapse.
Research continues to address two remaining major clinical questions. First, how and when will patients with nonrelapsing-remitting MS develop relapses, and second, how will relapsing remitting patients develop relapses? [www.ncbi.nlm.nih.gov/newscenter/Release/29_November_2002?pid=13710&nav_pos=189&search_terms=relapses#topic=relapses;status=RELEVE.